Skip to main content
Michael Severino, MD, Cardiology, Winfield, IL

MichaelJSeverinoMDFACC

Cardiology Winfield, IL

Echocardiography, Preventive Cardiology

Physician

Dr. Severino is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Severino's full profile

Already have an account?

  • Office

    25 N Winfield Rd
    Ste 500
    Winfield, IL 60190
    Phone+1 630-232-2800
    Fax+1 630-232-3895

Education & Training

  • Loyola University Medical Center
    Loyola University Medical CenterFellowship, Cardiovascular Disease, 1992 - 1995
  • Loyola University Medical Center
    Loyola University Medical CenterResidency, Internal Medicine, 1989 - 1992
  • Loyola University Chicago Stritch School of Medicine
    Loyola University Chicago Stritch School of MedicineClass of 1989
  • Marquette University
    Marquette UniversityBS in Engineering, Biomedical Engineering, 1981 - 1985

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1991 - 2026
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Fellow (FACC) American College of Cardiology

Press Mentions

  • AbbVie (ABBV) Reports Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease
    AbbVie (ABBV) Reports Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical and Endoscopic Outcomes in Patients with Crohn's DiseaseFebruary 24th, 2022
  • New Drug for Treatment of Major Depressive Disorder
    New Drug for Treatment of Major Depressive DisorderFebruary 23rd, 2022
  • RINVOQ® (Upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
    RINVOQ® (Upadacitinib) Receives U.S. FDA Approval for Active Psoriatic ArthritisDecember 14th, 2021
  • Join now to see all

Professional Memberships